Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Boehringer Ingelheim
Julphar
Cantor Fitzgerald
UBS
Chubb
Covington
Cerilliant

Generated: August 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,675,704

« Back to Dashboard

Title:Modified release formulations containing drug-ion exchange resin complexes
Abstract: A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
Inventor(s): Mehta; Ketan (Princeton, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee: Tris Pharma, Inc. (Monmouth Junction, NJ)
Filing Date:Jul 01, 2016
Application Number:15/200,786
Claims:1. An orally ingestible solid dose composition comprising: (A) barrier coated particulates which provide a modified release profile which comprises: (i) a particulate drug-cation exchange resin complex comprising at least one drug bound to a pharmaceutically acceptable water insoluble cation exchange resin, said complex being in a matrix which further comprises a water insoluble polymer or copolymer, or hydrophilic polymer, wherein the particulate drug-cation exchange resin complex-matrix is capable of passing through a number 40 mesh screen, and (ii) about 20 wt % to about 50 wt %, based on the weight of the drug-cation exchange resin complex, of a high tensile strength, water permeable, water insoluble, non ionic, modified release polymeric diffusion barrier coating which provides a modified release profile to said at least one drug in the drug-cation exchange resin complex-matrix defined in (i), said barrier coating having an elongation factor of about 125% to about 400%, wherein said at least one drug is amphetamine or dextro-amphetamine; and (B) at least one of (iiia) and/or (iiib): (iiia) an uncoated particulate dextro-amphetamine-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, wherein said uncoated dextro-amphetamine-cation exchange resin complex is dextro-amphetamine bound to a pharmaceutically acceptable water insoluble cation exchange resin, (iiib) an uncoated particulate amphetamine-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, wherein said uncoated amphetamine-cation exchange resin complex is amphetamine bound to a pharmaceutically acceptable water insoluble cation exchange resin, and optionally at least one of (iiic) and/or (iiid): (iiic) amphetamine or a pharmaceutically acceptable salt thereof which is not complexed with an ion exchange resin, and/or (iiid) dextroamphetamine or a pharmaceutically acceptable salt thereof which is not complexed with an ion exchange resin.

2. The orally ingestible solid dose composition according to claim 1, wherein the matrix comprises the water insoluble polymer or copolymer.

3. The orally ingestible solid dose composition according to claim 1, wherein the matrix comprises the hydrophilic polymer, wherein said hydrophilic polymer comprises polyvinylpyrrolidone.

4. The orally ingestible solid dose composition according to claim 1, wherein said high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating comprises about 30 wt % to about 45 wt % of the drug-cation exchange resin complex.

5. The orally ingestible solid dose composition according to claim 1 which comprises at least one of said uncoated particulate dextro-amphetamine-cation exchange resin as defined in (B)(iiia) and/or said uncoated particulate amphetamine-cation exchange resin as defined in (B)(iiib).

6. The orally ingestible solid dose composition according to claim 5 which comprises at least one of said amphetamine or pharmaceutically acceptable salt thereof as defined in (B)(iiic) or dextro-amphetamine or pharmaceutically acceptable salt as defined in (B)(iiid) which is not complexed with an ion exchange resin.

7. The orally ingestible solid dose composition according to claim 1 wherein said high tensile strength, water permeable, water insoluble non-ionic polymeric diffusion barrier coating further comprises a plasticizer in an amount of about 2% w/w to about 20 w/w % of the coating layer.

8. The orally ingestible solid dose composition according to claim 7, wherein said plasticizer comprises about 5% w/w to about 20% w/w of the coating.

9. The orally ingestible solid dose composition according to claim 1, wherein said cation exchange resin used to form the complex as defined in (A), (B)(iiia), and/or (B)(iiib) is a sulfonated copolymer comprising styrene and a divinylbenzene.

10. The orally ingestible solid dose composition according to claim 1, wherein said composition is a tablet.

11. An orally ingestible solid dose composition comprising: (A) barrier coated particulates which provide about a twelve-hour release profile which comprises: (i) a particulate drug-cation exchange resin complex comprising at least one drug bound to a pharmaceutically acceptable water insoluble cation exchange resin, said complex being in a matrix which further comprises a water insoluble polymer or copolymer, or hydrophilic polymer, wherein the particulate drug-cation exchange resin complex-matrix is capable of passing through a number 40 mesh screen, and (ii) about 30 wt % to about 50 wt %, based on the weight of the drug-cation exchange resin complex, of a high tensile strength, water permeable, water insoluble, non ionic, modified release polymeric diffusion barrier coating which provides a modified release profile to said at least one drug in said drug-cation exchange resin complex-matrix, said barrier coating having an elongation factor of about 125% to about 400%, wherein said at least one drug is amphetamine or dextro-amphetamine; and (B) at least one of (iiia) and/or (iiib): (iiia) an uncoated particulate dextro-amphetamine-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, wherein said uncoated dextro-amphetamine-cation exchange resin complex is dextro-amphetamine bound to a pharmaceutically acceptable water insoluble cation exchange resin, (iiib) an uncoated particulate amphetamine-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, wherein said uncoated amphetamine-cation exchange resin complex is amphetamine bound to a pharmaceutically acceptable water insoluble cation exchange resin, and optionally at least one of (iiic) and/or (iiid): (iiic) amphetamine or a pharmaceutically acceptable salt thereof which is not complexed with an ion exchange resin, and/or (iiid) dextroamphetamine or a pharmaceutically acceptable salt thereof which is not complexed with an ion exchange resin.

12. The orally ingestible solid dose composition according to claim 11, wherein the matrix comprises the water insoluble polymer or copolymer to form the drug-cation exchange resin complex-matrix as defined in (A).

13. The orally ingestible solid dose composition according to claim 11, wherein the matrix comprises the hydrophilic polymer to form the drug-cation exchange resin complex as defined in (A), wherein the hydrophilic polymer comprises polyvinylpyrrolidone.

14. The orally ingestible solid dose composition according to claim 11, wherein said high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating comprises about 35 wt % to about 50 wt % of the drug-cation exchange resin complex.

15. The orally ingestible solid dose composition according to claim 11 which comprises at least one of said uncoated particulate dextro-amphetamine-cation exchange resin as defined in (B)(iiia) and/or said uncoated particulate amphetamine-cation exchange resin as defined in (B)(iiib).

16. The orally ingestible solid dose composition according to claim 15 which comprises at least one of said amphetamine or pharmaceutically acceptable salt thereof as defined in (B)(iiic) or dextro-amphetamine or pharmaceutically acceptable salt as defined in (B)(iiid) which is not complexed with an ion exchange resin.

17. The orally ingestible solid dose composition according to claim 11 wherein said high tensile strength, water permeable, water insoluble non-ionic polymeric diffusion barrier coating further comprises a plasticizer in an amount of about 2% w/w to about 20% of the coating layer.

18. The orally ingestible solid dose composition according to claim 17, wherein said plasticizer comprises about 5% w/w to about 20% w/w of the coating.

19. The orally ingestible solid dose composition according to claim 11, wherein said cation exchange resin used to form the complex as defined in (A), (B)(iiia), and/or (B)(iiib) is a sulfonated copolymer comprising styrene and a divinylbenzene.

20. The orally ingestible solid dose composition according to claim 11, wherein said composition is a tablet.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Teva
Healthtrust
UBS
AstraZeneca
Citi
Fuji
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.